<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00884325</url>
  </required_header>
  <id_info>
    <org_study_id>XYZ0801</org_study_id>
    <nct_id>NCT00884325</nct_id>
  </id_info>
  <brief_title>Management of Pruritus With Xyzal in Atopic Dermatitis</brief_title>
  <official_title>Management of Pruritus With Xyzal in Atopic Dermatitis in a Randomized, Double-Blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Derm Research, PLLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Derm Research, PLLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is historically well known that the management of pruritus in atopic dermatitis is very
      difficult. Most of the patients are not controlled with traditional antihistamines such as
      Clarinex, Claritin, and Allegra. It will be a welcome addition to our treatment armamentarium
      if a drug such as Xyzal can control pruritus associated with atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pruritus VAS Scores at Baseline, Week 2 and Week 4</measure>
    <time_frame>Baseline - Week 2-Week 4</time_frame>
    <description>Consented subjects who met inclusion/exclusion criteria were assigned either 5mg levocetirizine dihydrochloride (Xyzal) or placebo to be taken daily each evening for 28 days. Subjects were asked to complete a Visual Analog Scale to measure itch at Baseline, Week 2 and Week 4. The scale is an eleven point scale ranging from 0-10 with 0 indicating no itch to 10 indicating itch that frequently interferes with daily activities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI) Questionnaire Scores at Baseline, Week 2 and Week 4</measure>
    <time_frame>Baseline - Week 2 - Week 4</time_frame>
    <description>Consented subjects who met inclusion/exclusion criteria were asked to complete a DLQI (Dermatology Life Quality Index)at Baseline, Week 2 and Week 4. The DLQI is a 10 item questionnaire broken down into 6 domains; symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment with a total score ranging from 0-30 (no effect on subject's life for 0, extremely large effect on subject's life for 30)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>Xyzal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocetirizine dihydrochloride (Xyzal)</intervention_name>
    <description>One tablet 5 mg taken orally at night for 28 days</description>
    <arm_group_label>Xyzal</arm_group_label>
    <other_name>Xyzal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>One tablet taken orally at night for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient, male or female subjects of any race, at least 18 years of age.

          -  Female subjects of childbearing potential must have a negative urine pregnancy test
             result at Baseline and practice a reliable method of contraception throughout the
             study. A female is considered of childbearing potential unless she is:

               -  postmenopausal for at least 12 months prior to study drug administration;

               -  without a uterus and/or both ovaries; or

               -  has been surgically sterile for at least 6 months prior to study drug
                  administration.

          -  Reliable methods of contraception are:

               -  hormonal methods or intrauterine device in use &gt; 90 days prior to study drug
                  administration;

               -  barrier methods plus spermicide in use at least 14 days prior to study drug
                  administration; or

               -  vasectomized partner. [Exception: Female subjects of childbearing potential who
                  are not sexually active will not be required to practice a reliable method of
                  contraception. These subjects may be enrolled at the Investigator's discretion if
                  they are counseled to remain sexually inactive during the study and understand
                  the possible risks in getting pregnant during the study.]

          -  Definitive diagnosis of atopic dermatitis as per Rajka-Hanifin criteria.

          -  Visual Analog Scale (VAS) pruritus score of 6 cm or more (moderate to severe itching)
             at baseline.

          -  Willing to refrain from other antihistamines and topical steroids and topical
             immunomodulators for the duration of the study.

          -  Able to understand and comply with the requirements of the study and sign Informed
             Consent/Health Insurance and Portability Accountability Act (HIPAA) Authorization
             forms.

        Exclusion Criteria:

          -  Female subjects who are pregnant (positive urine pregnancy test), breast-feeding, or
             who are of childbearing potential and not practicing a reliable method of birth
             control.

          -  Requiring oral treatment for their atopic dermatitis apart from oral antihistamines

          -  History of hypersensitivity or idiosyncratic reaction to to any component of the test
             medication , or to cetirizine.

          -  Atopic Dermatitis triggered by an unavoidable irritant/allergen.

          -  Skin disease/disorder that might interfere with the diagnosis or evaluation of atopic
             dermatitis (e.g., erythroderma, skin infection on the affected area, etc.)

          -  Non-compliance with the proper wash-out periods for prohibited medications.

          -  Uncontrolled chronic disease such as diabetes

          -  The presence of renal disease with mild, moderate or severe renal impairment

          -  Medical condition that, in the opinion of the Investigator, contraindicates the
             subject's participation in the clinical study.

          -  Clinically significant alcohol or drug abuse, in the opinion of the Investigator.

          -  History of poor cooperation, non-compliance with medical treatment, or unreliability.

          -  Participation in an investigational drug study within 30 days of the Baseline Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leon H. Kircik, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>DermResearch, PLLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DermResearch, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hannuksela M, Kalimo K, Lammintausta K, Mattila T, Turjanmaa K, Varjonen E, Coulie PJ. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy. 1993 Feb;70(2):127-33.</citation>
    <PMID>8430920</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2009</study_first_submitted>
  <study_first_submitted_qc>April 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2009</study_first_posted>
  <results_first_submitted>April 23, 2013</results_first_submitted>
  <results_first_submitted_qc>August 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 16, 2013</results_first_posted>
  <last_update_submitted>August 14, 2013</last_update_submitted>
  <last_update_submitted_qc>August 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Derm Research, PLLC</investigator_affiliation>
    <investigator_full_name>Leon Kircik, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Itching</keyword>
  <keyword>Atopic Dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levocetirizine</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects with uncomplicated atopic dermatitis were recruited form the PI's medical practice. Recruitment occurred from March 2009 through December 2009.</recruitment_details>
      <pre_assignment_details>45 subjects were consented but 5 were screen failures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subjects Receiving Xyzal</title>
          <description>one tablet, 5 mg, taken orally at night for 28 days</description>
        </group>
        <group group_id="P2">
          <title>Subjects Receiving Placebo</title>
          <description>one tablet taken orally at night for 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not provided</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects Receiving Xyzal</title>
        </group>
        <group group_id="B2">
          <title>Subjects Receiving Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age data was unknown for one placebo participant</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Age data was missing for one placebo participant</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" spread="14.6" lower_limit="19.5" upper_limit="64.6"/>
                    <measurement group_id="B2" value="41.1" spread="14.8" lower_limit="19.8" upper_limit="68.1"/>
                    <measurement group_id="B3" value="41.1" spread="14.6" lower_limit="19.5" upper_limit="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>gender data was missing for one participant</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pruritus VAS Scores at Baseline, Week 2 and Week 4</title>
        <description>Consented subjects who met inclusion/exclusion criteria were assigned either 5mg levocetirizine dihydrochloride (Xyzal) or placebo to be taken daily each evening for 28 days. Subjects were asked to complete a Visual Analog Scale to measure itch at Baseline, Week 2 and Week 4. The scale is an eleven point scale ranging from 0-10 with 0 indicating no itch to 10 indicating itch that frequently interferes with daily activities.</description>
        <time_frame>Baseline - Week 2-Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects Receiving Xyzal</title>
          </group>
          <group group_id="O2">
            <title>Subjects Receiving Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Pruritus VAS Scores at Baseline, Week 2 and Week 4</title>
          <description>Consented subjects who met inclusion/exclusion criteria were assigned either 5mg levocetirizine dihydrochloride (Xyzal) or placebo to be taken daily each evening for 28 days. Subjects were asked to complete a Visual Analog Scale to measure itch at Baseline, Week 2 and Week 4. The scale is an eleven point scale ranging from 0-10 with 0 indicating no itch to 10 indicating itch that frequently interferes with daily activities.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="6.5" upper_limit="8.5"/>
                    <measurement group_id="O2" value="7.5" lower_limit="7.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.10" lower_limit="1.6" upper_limit="7.5"/>
                    <measurement group_id="O2" value="5.9" lower_limit="3.65" upper_limit="7.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" lower_limit="2.4" upper_limit="6.9"/>
                    <measurement group_id="O2" value="6.4" lower_limit="2.5" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatology Life Quality Index (DLQI) Questionnaire Scores at Baseline, Week 2 and Week 4</title>
        <description>Consented subjects who met inclusion/exclusion criteria were asked to complete a DLQI (Dermatology Life Quality Index)at Baseline, Week 2 and Week 4. The DLQI is a 10 item questionnaire broken down into 6 domains; symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment with a total score ranging from 0-30 (no effect on subject's life for 0, extremely large effect on subject's life for 30)</description>
        <time_frame>Baseline - Week 2 - Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects Receiving Xyzal</title>
          </group>
          <group group_id="O2">
            <title>Subjects Receiving Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Life Quality Index (DLQI) Questionnaire Scores at Baseline, Week 2 and Week 4</title>
          <description>Consented subjects who met inclusion/exclusion criteria were asked to complete a DLQI (Dermatology Life Quality Index)at Baseline, Week 2 and Week 4. The DLQI is a 10 item questionnaire broken down into 6 domains; symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment with a total score ranging from 0-30 (no effect on subject's life for 0, extremely large effect on subject's life for 30)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DLQI - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="4.00" upper_limit="14.00"/>
                    <measurement group_id="O2" value="8.00" lower_limit="7.00" upper_limit="13.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DLQI - Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="2.00" upper_limit="6.5"/>
                    <measurement group_id="O2" value="5.5" lower_limit="2.00" upper_limit="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DLQI - Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="5.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="1.00" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Subjects Receiving Xyzal</title>
        </group>
        <group group_id="E2">
          <title>Subjects Receiving Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pruritus - worsening</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>seasonal allergies - worsening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sinus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of subjects. Of 40 subjects enrolled, only 33 completed the 4 week study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Leon H. Kircik, M.D.</name_or_title>
      <organization>DermResearch, PLLC</organization>
      <phone>502-451-9000</phone>
      <email>wedoderm@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

